https://www.oncologyeducation.com/infographics/download-infographics-novel-triplet-with-darolutamide-improves-os-for-mcspc/2024-10-10T17:05:34-04:00https://www.oncologyeducation.com/infographics/cdk-4-6-inhibitor-for-early-breast-cancer/2024-10-11T11:36:17-04:00https://www.oncologyeducation.com/infographics/ascertain-study-oraldecitabine-cedazuridine-is-a-viable-alternativeto-iv-decitabine-for-patients-with-mds-or-cmml/2025-07-30T13:37:38-04:00https://www.oncologyeducation.com/infographics/etude-ascertain-la-decitabine-cedazuridine-orale-est-une-alternative-viable-a-la-decitabine-iv-pour-les-patients-atteints-de-smd-ou-de-lmmc/2025-06-17T15:30:15-04:00https://www.oncologyeducation.com/infographics/flt3-mutations-in-refractory-and-relapsed-aml-clonal-evolution-resistance-mechanisms-and-implications-for-targeted-therapy/2025-11-20T12:09:56-04:00https://www.oncologyeducation.com/infographics/bridging-the-gap-the-first-pan-canadian-consensus-on-acute-radiation-dermatitis-ard-management-in-breast-cancer/2026-04-19T03:46:04-04:00https://www.oncologyeducation.com/infographics/ralu-study-sequential-use-of-radium-223-and-lutetium-177-in-mcrpc-treatment/2026-05-13T11:15:53-04:00https://www.oncologyeducation.com/infographics/relativity-047-4-year-update-nivolumab-relatlimab-in-advanced-melanoma/2026-02-04T16:27:39-04:00https://www.oncologyeducation.com/infographics/checkmate-8hw-nivolumab-ipilimumab-in-msi-h-dmmr-mcrc/2026-02-17T11:54:36-04:00https://www.oncologyeducation.com/infographics/physician-tool-for-patient-discussion-learning-to-identify-and-actively-report-adverse-events-with-lorlatinib/2026-03-06T13:25:26-04:00https://www.oncologyeducation.com/infographics/physician-education-tool-building-confidence-delivering-lorlatinib-treatmentfor-alk-mnsclc-and-managing-adverse-events/2026-03-06T13:10:27-04:00https://www.oncologyeducation.com/infographics/quizartinib-in-amlfrom-potent-flt3-inhibition-to-real-world-practice/2026-09-01T16:10:17-04:00